Results 241 to 248 of about 20,052 (248)

Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial.

JAMA Cardiol
Mulvagh SL, Inzucchi SE, Marx N, Poulter NR, Deanfield JE, Pop-Busui R, Emerson SS, Mann JFE, Engelmann MDM, Hovingh GK, Mandavya K, Davicevic-Elez Z, Jeppesen OK, Lorenzatti A, Oguz A, Mankovsky B, Deerochanawong C, Gorgojo-Martinez JJ, Ji L, Bain SC, McGuire DK, Buse JB, SOUL Study Group.   +22 more
europepmc   +1 more source

Investigating the Link Between Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Non-arteritic Ischemic Optic Neuropathy: A Case Report of Semaglutide-Induced Optic Neuropathy. [PDF]

Cureus
Bakheet M, Chaudhary A.
europepmc   +1 more source

AI-Enabled Personalization of Semaglutide Therapy in Type 2 Diabetes: Systematic Review With an Integration Framework. [PDF]

JMIR AI
Barakat G, El Hajj Hassan S, Akhdar H, Duong-Trung N, Ramadan W.   +4 more
europepmc   +1 more source

Semaglutide versus caloric restriction‐induced weight loss: insights into effects on skeletal muscle mass and function

The Journal of Physiology, EarlyView.
Harsh Shah, Julio E. Ayala
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Semaglutide

Reactions Weekly
  +36 more sources

Semaglutide

Reactions Weekly, 2023
  +8 more sources

Semaglutid

pharma-kritik, 2019
Semaglutid ist ein weiterer GLP-1-Rezeptoragonist, der nur einmal wöchentlich injiziert werden muss und wie z.B. Liraglutid makrovaskuläre Komplikationen reduziert. Das Nutzen/Risiko-Verhältnis einer chronischen Verabreichung ist noch nicht definitiv geklärt.
openaire   +1 more source

Cyanocobalamin/semaglutide/semaglutide

Reactions Weekly, 2023
openaire   +1 more source